ICU Medical (NASDAQ:ICUI) Updates FY 2025 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 6.550-7.250 for the period, compared to the consensus EPS estimate of 7.130. The company issued revenue guidance of -.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. KeyCorp boosted their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. Finally, Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, ICU Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.67.

ICU Medical Stock Performance

ICU Medical stock traded down $4.52 during mid-day trading on Thursday, reaching $149.75. 388,345 shares of the company traded hands, compared to its average volume of 201,601. ICU Medical has a fifty-two week low of $93.36 and a fifty-two week high of $196.26. The firm’s fifty day moving average is $160.70 and its two-hundred day moving average is $166.21. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The company has a market capitalization of $3.67 billion, a price-to-earnings ratio of -32.77 and a beta of 0.63.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.24. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. On average, equities research analysts expect that ICU Medical will post 4.11 earnings per share for the current fiscal year.

Insider Buying and Selling at ICU Medical

In related news, CEO Vivek Jain sold 1,373 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total value of $213,474.04. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $16,262,119.64. The trade was a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 6.70% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.